Regentis Biomaterials (NYSE American: RGNT) is positioning itself as a key player in the $3 billion U.S. knee cartilage repair market with its GelrinC platform, a potential first-in-class off-the-shelf solution that could simplify treatment and improve patient outcomes. According to a press release, GelrinC offers a single-step procedure that integrates into standard surgical workflows, eliminating the need for cells, delays, or complex handling.
Clinical data indicates that GelrinC provides approximately 100% greater pain improvement compared to microfracture, the current standard of care, with durable outcomes and MRI-confirmed regeneration of near-native cartilage. The procedure takes about 10 minutes and requires roughly two weeks of recovery, significantly shorter than cell-based therapies, which often involve lengthy rehabilitation and higher costs. This efficiency is expected to drive adoption among surgeons, payers, and patients.
The company estimates that the U.S. market for knee cartilage repair comprises approximately 470,000 annual cases, with no comparable ready-to-use competitor currently available. GelrinC is already CE Mark approved in Europe and is advancing through a pivotal Phase III trial in the U.S., approaching key catalysts such as commercialization and FDA submission.
Regentis is a regenerative medicine company focused on developing tissue repair solutions using its Gelrin platform technology, based on synchronized, degradable materials. The company’s initial focus is on knee injuries and other orthopedic treatments.
Forward-looking statements in the release caution that actual results may differ materially due to risks and uncertainties, including those detailed in the company’s SEC filings. Full terms and disclaimers are available on the InvestorBrandNetwork website.
The original press release can be viewed on NewMediaWire.
This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Regentis Biomaterials Targets $3 Billion Knee Cartilage Market with Off-the-Shelf GelrinC Platform.